NCT03040479View on ClinicalTrials.gov

Pharmacokinetic Single Dose Study of Oral Lasmiditan in Participants With Normal and Impaired Hepatic Function

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

March 14, 2017

Primary Completion Date

July 17, 2017

Study Completion Date

July 17, 2017

Conditions
Migraine
Interventions
DRUG

lasmiditan 200 mg

single dose

Trial Locations (3)

32809

Orlando Clinical Research Center, Orlando

37920

NOCCR, Knoxville

H3P 3P1

Altasciences Company Inc./Algorithme Pharma, Mount Royal

Sponsors
All Listed Sponsors
collaborator

Algorithme Pharma Inc

INDUSTRY

collaborator

CoLucid Pharmaceuticals

INDUSTRY

lead

Eli Lilly and Company

INDUSTRY

NCT03040479 - Pharmacokinetic Single Dose Study of Oral Lasmiditan in Participants With Normal and Impaired Hepatic Function | Biotech Hunter | Biotech Hunter